Paper Details

  1. Home
  2. Paper Details

Concomitant immune-related events in Wilson disease: implications for monitoring chelator therapy.

Author: FerenciPeter, GohdesAnnina, GotthardtDaniel Nils, PfeiffenbergerJan, SchäferMark, SeessleJessica, StremmelWolfgang, WeissKarl Heinz

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study assessed the prevalence of co-existing or therapy-related immune-mediated diseases in Wilson disease patients and evaluated the role of antinuclear antibodies in therapy monitoring.
Paper Details　
Original Abstract of the Article :
Current guidelines favor the use of chelating agents (d-penicillamine, trientine) in first line therapy of symptomatic Wilson disease patients. Development of chelator induced immunological adverse events are a concern especially under d-penicillamine therapy. This study assessed the prevalence of c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10545-015-9866-0

データ提供：米国国立医学図書館（NLM）

Immune-Related Events in Wilson Disease: Implications for Monitoring Chelator Therapy

Wilson disease, a genetic disorder affecting copper metabolism, can be a challenging condition to manage. This research delves into the potential complications associated with chelator therapy, a common treatment approach for Wilson disease. The researchers explore the prevalence of immune-mediated diseases in Wilson disease patients and the role of antinuclear antibodies in monitoring chelator therapy.

Navigating the Potential for Immune-Related Events

The study highlights the importance of monitoring for immune-related events, particularly when using d-penicillamine, a chelating agent commonly used to treat Wilson disease. The researchers found a significant prevalence of co-existing or therapy-related immune-mediated diseases in Wilson disease patients, underscoring the importance of careful monitoring during chelator therapy.

Personalized Monitoring for Optimal Outcomes

The study emphasizes the importance of personalized monitoring for Wilson disease patients undergoing chelator therapy. They suggest that antinuclear antibodies could serve as a valuable tool for monitoring the potential development of immune-related complications. By closely monitoring these biomarkers, clinicians can adjust treatment strategies as needed, minimizing the risk of adverse events and optimizing patient outcomes.

Dr. Camel's Conclusion

Managing Wilson disease requires a delicate balance between treating the underlying copper imbalance and minimizing the risk of complications. This research underscores the importance of vigilant monitoring during chelator therapy, particularly for immune-related events. By understanding the potential for these complications and implementing proactive monitoring strategies, we can improve the long-term well-being of individuals with Wilson disease, helping them navigate the desert landscape of their condition with greater confidence.

Date :
  1. Date Completed 2016-10-17
  2. Date Revised 2019-01-14
Further Info :

Pubmed ID

26067812

DOI: Digital Object Identifier

10.1007/s10545-015-9866-0

Related Literature

Article Analysis
・Side Effects of penicillamine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.